Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Breakthrough treatment after years of only modest progress in heart failure
+Print Archive
South GP CME
Breakthrough treatment after years of only modest progress in heart failure
Wednesday 28 August 2019, 07:00 AM

Heart Foundation GP liaison Joan Leighton and medical director Gerry Devlin see promise in new heart-failure drug Entresto
Entresto is not a ‘flash in the pan’ but a genuine breakthrough. In time, it will become a standard treatment for heart failure
A new drug for he
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. McMurray JV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
2. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ 2019;364:l223 (online 13 February).